Silihan lan utang jangka dawa perusahaan: 89bio Corp (ETNB)

89bio, Inc. ensures the preservation of biomaterials through diversified logistics channels, although the business is heavily dependent on the outcome of its lead drug trials. Changes in the company's long-term debt reflect liability dynamics, where 0.04 shows the current volume of this metric. Simultaneously, 89bio, Inc. is implementing energy-saving technologies and reducing toxic waste in laboratories in accordance with ESG environmental standards.

Long-term debt reflects the aggregate of obligations with maturities exceeding twelve months, allowing investors to assess the stability of the capital structure and default risks. By analyzing the magnitude of the company's long-term debt on GURU.Markets, one can understand how effectively 89bio, Inc. (ETNB) finances the development of metabolic liver disease therapies to ensure future stable patent revenues and long-term business capitalization.